Abstract

Sciresol

https://jmsh.ac.in/

Journal of Medical Sciences and Health

10.46347/jmsh.v8i2.22.5

ORIGINAL ARTICLE

Evaluation of Anxiolytic Activity of Ondansetron in mice models — An Animal Experimental Research

Evaluation of anxiolytic activity of ondansetron in mice models

Jain

Vipin Kumar

1 Shilpa

Kaore Navinchandra

2 Rajnish

Sankadia

3 Megha

Jain

megha.vipin12@gmail.com 4 Ritesh

Upadhyay

5 Dileep

Dandotiya

6 Assistant Professor, Department of Pharmacology, Chhindwara Institute of Medical Sciences

Chhindwara (M.P)

India Additional Professor, Department of Pharmacology, All India Institute of Medical Sciences

Bhopal (M.P)

India Assistant Professor, Department of Pharmacology, Bundelkhand Medical College

Sagar (M.P)

India Assistant Professor, Department of Dentistry, Chhindwara Institute of Medical Sciences

Chhindwara (M.P)

India Assistant Professor, Department of Community Medicine, Chhindwara Institute of Medical Sciences

Chhindwara (M.P)

India Demonstrator, Department of Community Medicine, Chhindwara Institute of Medical Sciences, Chhindwara Institute of Medical Sciences

Chhindwara (M.P)

India

8 2 106

2022

Abstract

Background: Anxiety and depression are the common mental disorders, which affect the general population upto 15%, once at their life span and an important reason of disability in world with high impact on social-economic status of affected persons. The Benzodiazepines preferred for the treatment of generalized anxiety as they provide immediate relief, however the high potential for abuse and dependence, limits the utilization of Benzodiazepines. Literature suggests that increased serotonergic neurotransmission in synapse leads to allosteric modulation of serotonergic system by 5-HT_1Apartial agonists and with the blockade of 5-HT₃receptor by its antagonists develop anti anxiety effect which may serve as alternatives to Benzodiazepines as anxiolytic because of lesser side effects and better tolerability with favourable pharmacological records in patients. Objective: To evaluate anxiolytic activity of ondansetron in mice model. Material and methods: Male Swiss albino mice (20-30 g BW) were divided in five groups. Study was undertaken after approval from IAEC, People’s College of Medical Science and Research Centre, Bhopal. Animals received intraperitoneally either Ondansetron (0.1, 0 .5 and 1mg/kg), diazepam (1mg/kg) in intervention group or vehicle (1ml dw) in control. Elevated plus maze and hole board test were used to compare the effects of ondansetron with diazepam for evaluation of anxiolytic activity. In addition, assessment of drugs on motor activity was done by photo actometer. Result: Ondansetron exhibited significant anxiolytic activity at 0.5, 1.0 mg/kg BW dose. Comparison between groups shows significant variation (p<0.05) in dose dependent manner. Locomotor activity was not significantly changed by ondansetron at these test doses. Conclusion: Ondansetron was found to exhibit significant anxiolytic activity in mice models. Further researches are required for elucidating the mechanism and to explore its role in psychopharmacology and its therapeutic application in various psychiatric disorders including anxiety.

Keywords Ondansetron Anxiolytic Benzodiazepines INTRODUCTION

Anxiety and depression are the common mental disorders, affecting the general population upto 15% and also an important reason of disability in world with significant impact on social-economic status of affected individuals.^{1, 2, 3}Data from the 2019 National Health Interview Survey (NHIS) in American population, estimated 1 in 6 adults aged 18 years and above have anxiety symptoms with predominant age group between 18-29 years. Also women were experiencing higher (19%) anxiety symptoms as compared to men (11.9%). ⁴

The National Mental Health Survey 2015-16 conducted across 12 states in India revealed that neurotic and stress-related disorders (F40–F48) having lifetime prevalence of 3.70 % and there is a large treatment gap nearly 84% for anxiety disorders raising concern. ⁵

Anxiety is a disorder having both psychological and physiological symptoms including fear, apprehension, poor concentration, and complaints related to different organ system. The commonly utilized medicines groups for the treatment of anxiety are benzodiazepines (BZDs), azapirones, selective serotonin reuptake inhibitors (SSRIs) and beta blockers.6 The BZDs are preferred for the treatment of generalized anxiety as they provide immediate relief, although for long term therapy, SSRIs were more effective as compared to BZDs.7 5-HT_1A agonist serve as alternatives, that relieves generalized anxiety of mild-moderate intensity but is found to be ineffective in severe cases, the maximum benefits are delayed upto 2-3 weeks, acts by stimulating 5-HT_1A autoreceptors8 Taking this into account, and the high potential for abuse and dependence, limits the utilization of BZDs as well as side effects of SSRIs reported in patients like loss of libido, insomnia, diminished arousal, delayed orgasm increased weight etc. 9 there is scope for newer strategies to serve as alternative in this condition.Hence, there is continuing search for newer compounds having lesser side effects due to narrow safety margin between an anxiolytic effect and unwanted adverse effects of BZDs.^{10, 11}

The involvement of central nervous system in causation of anxiety was hypothesized by participation of both adrenergic and serotonergic systems in terms of either over activity of adrenergic systems and/ or the dysregulation of serotonergic systems.¹² Animal studies based on targeted gene deletion of the 5-HT_3A receptor subunit produces an anxiolytic phenotype in mice suggesting involvement of 5-HT₃receptor in developing anxiety like behaviour. ¹³Earlier also studies have been done based on animal models of anxiety to study the role of 5-HT₃ receptor antagonists as anxiolytic like effect.14The 5 HT₃ receptor antagonists have lesser side effects and better tolerability with favourable pharmacological records in patients15 similar to azapirones.

Hence the present study has been undertaken to elucidate anxiolytic activity (AA) of a 5-HT₃ receptor antagonist, namely Ondansetron (OND) in mice models.

MATERIALS AND METHODS

Study was approved by IAEC (CPCSEA Reg.No- 1120/ac/07/CPCSEA) and animals were maintained according to the CPCSEA guidelines. Animals were kept in 12:12 hour light and dark cycle each, temperature 21-23 °C with relative humidity 50-60% conditions for at least 1 week before the experiments and were housed in groups of five. The animals were allowed free access to food (standard pellet ‘chow’ feed) and filtered water ad libitum. All behavioral tests conducted during light phase between 10.00 and 14.00. Swiss albino mice approximate of 6-8 weeks of age, weighing 20-40 gram were randomly divided into five study groups. All experimental groups included six animals with true efforts taken to limit the number and utilization of animals and to take a best possible way to maintain their comfort. Each animal was tested only once for each experiment. The AA was determined primarily by behavior based models, elevated plus maze (EPM) test ^{16, 17} and hole board test (HBT) ¹⁸to achieve a level of accuracy in predicting clinical activity that could not be assessed by a single test alone and in fact there is heterogeneity behind the etiology of anxiety disorders with involvement of different neurobiological components for each type and it is quite unattainable that a single testing method can be sufficient to includes all parameters of complex expression anxiety.19 An attempt was also made to rule out any bias due to influence of drug on locomotor activity, since we had also evaluated the parameter with photoactometer. At first, we carried out the dose response studies by using the mouse spontaneous locomotor activity test, EPM and HBT, to determine the effective and sub effective doses of these drugs without affecting the baseline locomotor status. These doses and times of administration were based upon previous reports.²⁰

In present study, Group I served as control and received 1 ml dw i.p, Group II to IV received OND 0.1 mg/kg, i.p., 0.5 mg/kg, i.p., 1mg/kg, i.p. respectively and Group V received diazepam 1mg/kg, i.p. as a standard anxiolytic. The apparatus in each model was cleaned with 10 % ethanol after the experiment with each animal to eliminate the likely bias due to body odor of previous animal. All behavioral testing were conducted in dimly lit and soundproof room during the same time of the day to minimize the confounding influence of any diurnal variations in animal spontaneous behavior.

<bold id="strong-39eea04c18d149e3865998cf08434206">Elevated Plus Maze (EPM) </bold>

EPM test validation for measurement of anxiety in rodents has been done in earlier studies.21 The EPM apparatus has two closed arms (50×10×40 cm) crossed with two open arms (50×10 cm) with an open roof, and connected to a central square (10×10 cm) to give it a plus sign appearance. The arms of the same types were located opposite to each other. The entire maze is raised 50 cm above the ground. After 30 minutes of drug administration, the mouse was placed individually in the central square of the maze facing one of the closed arms.¹⁶

The number of entries and time spent in each type of arm (open/closed) was recorded for 5 min.¹⁷An entry was defined as the presence of all four paws in the arm.

<bold id="strong-f032d79ccaaa422b8a140290bdc65e13">Hole Board test (HBT)</bold>

It consists of square wooden board (40x40 cm) divided into 9 equal squares with 16 equidistant holes, raised 25 cm above the ground. The mouse was placed individually in the centre of the board for 3 minutes, and their exploratory behavior in the form of head dipping and crossing of the lines of the squares by both forepaws was recorded. A head dip was counted if both eyes disappeared into the hole. The drug or vehicle was administered 30 minutes before the test.

<bold id="strong-a6d34b845827471d8472f30c196e522e">Measurement of Locomotor Activity (LA)</bold>

Neuropharmacological studies have been shown that there may be chances of false positive outcome in form of either general increase or decrease in LA in animal studies which was based on immobility time measurements and exploratory behavior assessment ²²

For this reason, the basal LA was assessed to find out the effects of drug treatment as compared to control on locomotor scores. To rule out any effects of the test drugs on motor activity of tested animals, horizontal LA of control and test were recorded for a period of five minutes using photoactometer.²³

The photoactometer consisted of a square arena (30cm×30cm) with walls painted black and having photocells above the floor level and connected to a circuit with a counter. Before commencement of the experiment photocells were checked. The principle of photocell is that the rays of light falling on the photocells are cut off by the animals crossing the beam of light and photocell activated, a count is recorded by an electronic automatic counting device in the form of number of cut offs.

The animals were placed individually in the photoactometer cage and after initial familiarization period of two minutes, digital locomotor score was recorded for the next five minutes. The experiment arena was cleaned with dilute alcohol (70% v/v) and stays dried between the tests to get rid of odour of previous animals.

<bold id="strong-efe4c603727f4234a44a1e890b4f0a4a">Statistical analysis</bold>

Data was analysed by using SPSS (20.0) software. The results were expressed as Mean ±SD. One-way analysis of variance (ANOVA) test were applied for statistical comparison. For all tests, significant main effects or interactions were resolved using post hoc ANOVAs with adjusted p-values and/or post hoc test (Tukey’s HSD). For statistical purpose the level of significance was set at P<0.05.

RESULT

In present study we found that OND increasing the number of entry and the time spent in the open arm as well as reduction in time spent in closed arms in EPM and increases the head dipping and crossing of line of square in the HBT, hence depicting AA. This increased number of entry and the time spent in the open arm in EPM and increased head dipping behavior and crossing of line of square in the HBT methods were statistically significant (P<0.0001).

The observation in EPM showed that numbers of entries in open arm were more in dose of 1 mg/kg (7.83±3.18) than 0.5 mg/kg dose (5.00±0.63) and 0.1 mg/kg (5.50±0.54) dose of OND as compared to control (5.00+0.89) and these observations were significant only with the higher dose of OND i.e. 1 mg/kg as compared to control but not with the dose of 0.1 mg/kg and 0.5 mg/kg of OND. (Table 1)

Table 1 <bold id="s-ff3e131a4d0b">Effect of Ondansetron and Diazepam on mice behavior in EPM</bold>

Drugs	No. of entry		Time spent (sec)
Drugs	Open arm	Close arm	Open arm	Close arm
Ondansetron 0.1 mg/kg	5.50 ± 0.54	21.00 ±1.26	28.54 ± 1.46	186.55 ± 2.74
Ondansetron 0.5 mg/kg	5.00 ± 0.63	11.66 ± 1.36	55.99 ±2.02	120.14 ± 1.70
Ondansetron 1 mg/kg	7.83 ± 3.18	12.50 ± 2.42	72.84 ±3.99	98.04 ± 6.87
Diazepam 1 mg/kg	14.5 ± 1.30	10.33 ±1.21	112.04± 3.94	53.94 ±1.61
Control	5.00 ±0.89	17.83 ± 2.13	50.89 ± 0.73	158.08 ± 3.11

Effect of Ondansetron (0.1, 0.5 and 1mg/kg i.p.) and diazepam 1 mg/kg i.p. on mice behavior in EPM, measured as number of entries in open and closed arms and time spent in seconds in open and closed arms.

Values represents Mean ±SD. p<0.05 significant as compared to control group, number of animals n=6 per group.

In EPM test, the time spent in open arm by mice were also observed and found that with the dose of 1 mg/kg of OND it was (72.84 ±3.99) which was more compared to the dose of 0.5 mg/kg (55.99 ±2.02 ) and 0.1 mg/kg (28.54 ± 1.46) of OND as compared to control (50.89 ± 0.73). These observations were significant as compared to control with dose of 1 mg/kg and 0.5 mg/kg of OND. (Table 1)

In present study, we found that in EPM the duration of time spent in closed arm were gradually decreasing as the dose increased i.e. with the dose of 0.1 mg/kg it was (186.55 ± 2.74) seconds which was more than the 0.5 mg/kg (120.14 ± 1.70) and 1 mg/kg (98.04 ± 6.87) dose of OND. The time spent in closed arm in EPM test was statistically significant as compared to control (158.08 ± 3.11) with dose of 0.5 mg/kg and 1 mg/kg of OND. (Table 1)

In HBT, the head dipping count was more in dose of 1 mg/kg (28.83 ± 4.79) than 0.5 mg/kg dose (21.83+4.62) and 0.1 mg/kg (6.16+2.13) dose of OND as compared to control (4.83+1.94) and these observations were significant only with the higher dose of OND i.e. 0.5 mg/kg and 1 mg/kg as compared to control but not with the dose of 0.1 mg/kg of OND. (Table 2)

Table 2 <bold id="s-32c2513d6777">Effect of Ondansetron and Diazepam on mice behavior in HBT</bold>

Drugs	No. of head dipping	Crossing of line of square
Ondansetron 0.1 mg/kg	6.16 ± 2.13	18.66 ±5.08
Ondansetron 0.5 mg/kg	21.83 ± 4.62	47.66 ± 22.47
Ondansetron 1 mg/kg	28.83 ± 4.79	53.33 ±4.92
Diazepam 1 mg/kg	25.50 ± 3.78	56.33± 5.75
Control	4.83 ±1.94	12.33 ±2.33

Effect of Ondansetron (0.1, 0.5 and 1mg/kg i.p.) and Diazepam 1 mg/kg i.p. on mice behavior in HBT, measured as number of head-dipping and crossing of line of square.

The exploratory behavior of mouse in form of crossing of line of square were also observed in HBT and was more evident with the test dose of 1 mg/kg of (53.33+4.92) OND as compared to dose of 0.5 mg/kg (47.66±22.47), and 0.1 mg/kg (18.66±5.08) of OND and control (12.33±2.33). However, these finding were significant only with the dose of 1 mg/kg and 0.5 mg/kg of OND as compared to control. (Table 2)

In EPM test, observation showed number of entries in open arm was significantly increased with diazepam 1 mg/kg (14.5 ± 1.30) as compared to control (5.00 ±0.89) as well as the time spent in open arm with diazepam 1mg/kg (112.04± 3.94) was more than the control (50.89 ± 0.73) and values were statistically significant. The reduction of time spent in closed arm was also significant with diazepam 1 mg/kg (53.94 ±1.61) as compared to control (158.08 ± 3.11). (Table 1)

The results showed that standard anxiolytic drug diazepam (1 mg/kg ) also significantly increased the number of head dipping (25.50 ± 3.78) as compared to control (4.83 ±1.94) and number of crossing of line of square (56.33± 5.75) as compare to control (12.33 ±2.33 ) in HBT. (Table 2)

Observations with OND in dose of 1 mg/kg showed lesser anxiolytic-like activity (ALA) in comparison to the standard drug diazepam 1mg/kg in both HBT and EPM, that was statistically significant (P<0.0001).

In our present study, spontaneous horizontal LA was not significantly affected by OND in all test doses (0.1, 0.5 and 1mg/kg i.p.), as well as with the standard drug diazepam (1 mg/kg i.p.) (Table 3)

Table 3 <bold id="s-32da2dfc6a0b">Effect of Ondansetron and Diazepam on Locomotor activity score</bold>

Drugs	Dosage	Locomotor activity counts/5 min, Mean ± S.D
Ondansetron	0.1mg/kg	296.64 +10.45
Ondansetron	0.5 mg/kg	302.24 + 11.64
Ondansetron	1mg/kg	288.38 +12.41
Diazepam	1mg/kg	295.00 +10.69
Control	1 ml dw	303.75 + 9.12

Effect of Ondansetron (0.1, 0.5 and 1mg/kg i.p.) and diazepam 1 mg/kg i.p. on locomotor activity score.

Values represents Mean±SD. p<0.05 significant as compared to control group, number of animals n= 6 per group.

DISCUSSION

In EPM model, avoidance of entry and staying in open arms and preference for the closed arms by animals indicates anxiety behavior. The EPM having a high validity as behavior based model to elicit ALA of medicines as it utilizes the natural stimulus like fear of facing a new open space and also fear of balancing on a narrow elevated alleys. Therefore, the medicines which produced effect of increased preference to entry as well as time spending in open arms without significantly changing the LA are considered to be anxiolytic- like medicines. ²¹For evaluation of AA of non BZDs medicines also, EPM can be utilized as a tool.²⁴In present study, the increased entries in open arm and increased time spent in open arm as well as decreased time spent in closed arm in EPM indicating AA of OND. Wright IK, et al found similar observations in EPM on rats. ²⁴ Also, Shenoy S et al ²⁵in a comparative animal study between the OND, granisetron and alprazolam as standard anxiolytic, found that OND at the dose of 1 mg/kg showed ALA in EPM which is in accordance with our study. However, the change in number of entries in arms (open/close) was not found to be significant in their study while in our present study we have found the significant changes with dose of 1 mg/kg of OND for the same but not with the lower dose i.e. 0.5 mg/kg and 0.1 mg/kg of OND.

An earlier study by Nevins ME and Anthony EW has shown that 5 HT₃ receptor antagonists OND and granisetron both reduced the startle response in rats which was potentiated by the fear suggesting anxiolytic like effects of 5 HT₃ receptor antagonists.²⁶

The HBT observation in our study is in accordance with the study by Kurhe Y and Mahesh R ²⁷ in a comorbid depression and anxiety associated with obesity model i.e. OND at the dose of 0.5 mg/kg and 1 mg/kg significantly increased the number of head dipping as well as increased the crossing of line of square suggesting potential ALA of OND. Study by Gupta D et al ²⁸ based on depression and anxiety like behavior in streptozocin induced diabetic mice model found that the OND at the dose of 1 mg/kg significantly increased the number of head dipping in HBT but not with the dose of 0.5 mg/kg of OND which is in accordance with our study.

Kurhe YV et al have found anxiolytic potential in EPM and HBT and other behavioral test in mice by using novel 5HT₃receptor antagonist.29 However, the mechanism of action was not exactly known but literature suggest that blockade of post synaptic located 5HT₃ serotonergic receptor increases the neurotransmission of serotonin which act through allosteric modulation of serotonergic system on other serotonin receptor 5HT₁and 5HT₂leads to development of anti anxiety effect. ³⁰

In conclusion, the present study revealed that OND may have ALA in dose dependent manner although not equivalent to standard anxiolytic diazepam. The possible mechanism is attributed to augmented serotonergic transmission in various part of the brain by OND.²⁰

However, the exact molecular mechanism behind anxiolytic action of OND is not clear and yet to establish. Although present study provides a potential alternative for treatment of anxiety keeping the concern of risk of abuse and dependence liability of BZDs in long duration therapies.

References

O’donnell

J M

Bies

R R

Shelton

R C

Brunton LL

Hilal-Dandan R

Knollman BC

Goodman and Gilman’s the pharmacological basis of therapeutics New York 2018 267 267

Ernst

Herbal remedies for anxiety – a systematic review of controlled clinical trials

Phytomedicine 2006 13 3 205 208 0944-7113

Elsevier BV

https://doi.org/10.1016/j.phymed.2004.11.006

Baxter

A J

Scott

K M

Vos

Whiteford

H A

Global prevalence of anxiety disorders: a systematic review and meta-regression

Psychological Medicine 2013 43 5 897 910 0033-2917

Cambridge University Press (CUP)

https://doi.org/10.1017/s003329171200147x

Terlizzi

E P

Villarroel

M A

Symptoms of Generalized Anxiety Disorder among Adults:United States

NCHS Data Brief 2019 378 1 8 https://pubmed.ncbi.nlm.nih.gov/33054928/

Gururaj

Varghese

Benegal

Rao

G N

Pathak

Singh

L K

National Institute of Mental Health and Neuro Sciences, NIMHANS Publication No. 129, 2016

National Mental Health Survey of India, 2015-16: Prevalence, patterns and outcomes

2016

NIMHANS Publication

Eisendrath

S J

McPhee SJ

Papadakis MA

Psychiatric disorders

Current medical diagnosis and treatment 2009

New York

914 918

Debattista

Katzung

B G

Masters

S B

A J Trevor

Antidepressant agents

Basic and Clinical Pharmacology 2009 521

Tripathi

K D

Tripathi

K D

Drugs Used in Mental Illness: Antidepressant and Antianxiety Drugs

Essentials of medical pharmacology Jaypee Brothers Medical Publishers (P) Ltd. 2019 439

Baldessarini

R J

Drug therapy of depression and anxiety disorders

Goodman & Gilman’s The pharmacological basis of therapeutics 11 2006 430 450

Grundmann

Oliver

Nakajima

Jun-Ichiro

Seo

Shujiro

Butterweck

Veronika

Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test

Journal of Ethnopharmacology 2007 110 3 406 411 0378-8741

Elsevier BV

https://doi.org/10.1016/j.jep.2006.09.035

Griffiths

R R

Ator

N A

Roache

J D

Lamb

R J

Abuse Liability of Triazolam: Experimental Measurements in Animals and Humans

Psychopharmacol Ser 1987 3 83 87

Springer Berlin Heidelberg

https://doi.org/10.1007/978-3-642-71288-3_10

Ressler

Kerry J

Nemeroff

Charles B

Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders

Depression and Anxiety 2000 12 S1 2 19 1091-4269

Wiley

https://doi.org/10.1002/1520-6394(2000)12:1+%3C2::aid-da2%3E3.0.co;2-4

Bhatnagar

Seema

Sun

Linda M

Raber

Jacob

Maren

Stephen

Julius

David

Dallman

Mary F

Changes in anxiety-related behaviors and hypothalamic–pituitary–adrenal activity in mice lacking the 5-HT-3A receptor

Physiology & Behavior 2004 81 4 545 555 0031-9384

Elsevier BV

10.1016/j.physbeh.2004.01.018

Olivier

Wijngaarden

I Van

Soudijn

5-HT3 receptor antagonists and anxiety; a preclinical and clinical review

European Neuropsychopharmacology 2000 10 2 77 95 0924-977X

Elsevier BV

https://doi.org/10.1016/s0924-977x(99)00065-6

Greenshaw

Andrew J

Silverstone

Peter H

The Non-Antiemetic Uses of Serotonin 5-HT3 Receptor Antagonists

Drugs 1997 53 1 20 39 0012-6667

Springer Science and Business Media LLC

Rodgers

R J

Dalvi

Anxiety, defence and the elevated plus-maze

Neuroscience & Biobehavioral Reviews 1997 21 6 801 810 0149-7634

Elsevier BV

https://doi.org/10.1016/s0149-7634(96)00058-9

Walf

Alicia A

Frye

Cheryl A

The use of the elevated plus maze as an assay of anxiety-related behavior in rodents

Nature Protocols 2007 2 2 322 328 1754-2189

Springer Science and Business Media LLC

https://doi.org/10.1038/nprot.2007.44

Boissier

J R

Simon

Dissociation de duex composantes dans le comportment d- investigation de la souris

Arch Int Pharmacodyn 1964 147 372 387

Bourin

Michel

Petit-Demoulière

Benoit

Dhonnchadha

Brid Nic

Hascöet

Martine

Animal models of anxiety in mice

Fundamental & Clinical Pharmacology 2007 21 6 567 574 0767-3981

Wiley

https://doi.org/10.1111/j.1472-8206.2007.00526.x

Ramamoorthy

Rajkumar

Radhakrishnan

Mahesh

Borah

Minasri

Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models

Behavioural Pharmacology 2008 19 1 29 40 0955-8810

Ovid Technologies (Wolters Kluwer Health)

https://doi.org/10.1097/fbp.0b013e3282f3cfd4

Pellow

Sharon

Chopin

Philippe

File

Sandra E

Briley

Mike

Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

Journal of Neuroscience Methods 1985 14 3 149 167 0165-0270

Elsevier BV

https://doi.org/10.1016/0165-0270(85)90031-7

O’neil

M F

Moore

N A

Animal models of depression: are there any

Hum. Psychopharmacol 2003 18 239 254 https://doi.org/10.1002/hup.496

Dews

P B

The measurement of the influence of drugs on voluntary activity in mice

British Journal of Pharmacology and Chemotherapy 1953 8 1 46 48 0366-0826

Wiley

https://doi.org/10.1111/j.1476-5381.1953.tb00749.x

Wright

Ian K

Heaton

Upton

Marsden

C A

Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze

Psychopharmacology 1992 107 2-3 405 414 0033-3158

Springer Science and Business Media LLC

https://doi.org/10.1007/bf02245168

Shenoy

Mohan

Saravanan

Kumar

Ramani

A comparative study of the effect of ondansetron,Granisetron and alprazolam on anxiety in wistar rats

International Journal of Applied Biology and Pharmaceutical Technology 2011 2 3 104 113

Nevins

Anthony

E W

Antagonists at the serotonin 3 receptor can reduce the fear potentiated startle response in the rat : evidence for different types of anxiolytic activity?

J Pharmacol Exp Ther 1994 268 1 248 254 https://pubmed.ncbi.nlm.nih.gov/7905528/

Kurhe

Yeshwant

Mahesh

Radhakrishnan

Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission

Pharmacology Biochemistry and Behavior 2015 136 107 116 0091-3057

Elsevier BV

https://doi.org/10.1016/j.pbb.2015.07.004

Gupta

Deepali

Radhakrishnan

Mahesh

Kurhe

Yeshwant

Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system

European Journal of Pharmacology 2014 744 59 66 0014-2999

Elsevier BV

https://doi.org/10.1016/j.ejphar.2014.09.041

Kurhe

Yeshwantvijay V

Radhakrishnan

Mahesh

Thangaraj

Devadoss

Gupta

Deepali

Anti-anxiety effect of a novel 5-HT<sub>3</sub>receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice

Indian Journal of Pharmacology 2014 46 1 100 100 0253-7613

Medknow

Kilpatrick

G J

Butler

Ireland

S J

Michel

A D

Tyers

M B

Affinities of 5-HT uptake inhibitors for 5-HT, receptors in both binding and functional studies

Br J Pharmacol 1989 98 859